TrianglePHOEBE (NCT05900895)
PHOEBE trial for Advanced ER-Positive HER2-Negative Breast Cancer (NCT05900895). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for postmenopausal adults with advanced estrogen receptor positive, HER2 negative breast cancer.
The idea: combine olaparib, a targeted pill, with estradiol, a form of estrogen taken by mouth three times a day. The study looks for a safe dose of the combination to use in a later phase.
This phase 1 study plans 6 patients. At Dartmouth-Hitchcock Medical Center, Mary Chamberlin leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.